Skip to main content
Terug
Watch Compare

Dogwood Therapeutics, Inc.

Datakwaliteit: 83%
DWTX
Nasdaq Manufacturing Chemicals
€ 2,00
▲ € 0,06 (3,09%)
Marktkapitalisatie: 66,59 M
Prijs
€ 2,00
Marktkapitalisatie
66,59 M
Dagbereik
€ 1,97 — € 2,11
52-Weeksbereik
€ 1,77 — € 9,50
Volume
37.586
Openen € 2,06
50D / 200D Gem.
€ 2,82
29,07% below
50D / 200D Gem.
€ 4,60
56,49% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -15,62 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-484,66%
Onder sectorgemiddelde (-51,02%)
ROIC-23,99%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio4,49
Interest CoverageN/A

Waardering

PE (TTM)
-1,94
Boven sectorgemiddelde (-1,98)
P/B Ratio9,17
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (44 peers)
Metriek Aandeel Sector Mediaan
P/E -1,9 -2,0
P/B 9,2 5,1
ROE % -484,7 -51,0
Net Margin % -150,2
Rev Growth 5Y % 9,3
D/E 0,3

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -34,26 M
ROE -484,66% ROA -36,31%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -15,62 M
ROIC -23,99% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,49
Interest Coverage N/A Asset Turnover N/A
Working Capital 9,06 M Tangible Book Value -72,87 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,94 Forward P/E N/A
P/B Ratio 9,17 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -23,45%
Market Cap 66,59 M Enterprise Value 56,46 M
Per Share
EPS (Diluted TTM) -7,13 Revenue / Share N/A
FCF / Share -0,47 OCF / Share -0,47
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 45,59%
SBC-Adj. FCF -15,96 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue
Net Income -34,26 M -12,35 M -5,30 M -12,25 M -15,96 M
EPS (Diluted) -7,13 -12,52 -0,28 -1,11 -1,92
Gross Profit
Operating Income -27,97 M -12,23 M -5,45 M -12,32 M -15,64 M
EBITDA
R&D Expenses 21,87 M 3,53 M 1,73 M 8,07 M 10,80 M
SG&A Expenses
D&A
Interest Expense 150.904,0 67.475,0 5.672,0
Income Tax 221.096,0 -503,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 90,17 M 94,31 M 4,17 M 8,37 M 15,78 M
Total Liabilities 15,27 M 30,03 M 358.548,0 1,04 M 1,28 M
Shareholders' Equity 74,90 M -10,12 M 3,81 M 7,33 M 14,50 M
Total Debt
Cash & Equivalents 6,52 M 14,85 M 3,32 M 7,03 M 14,01 M
Current Assets 8,43 M 16,54 M 4,17 M 8,37 M 15,78 M
Current Liabilities 3,06 M 3,18 M 358.548,0 1,04 M 1,28 M